Impact of hydroxymethylglutaryl coenzyme A reductase inhibition on left ventricular remodeling after myocardial infarction: An experimental serial cardiac magnetic resonance imaging study

Journal of the American College of Cardiology

Volumn 40, Issue 9, 2002, Pages 1695-1700

  Nahrendorf, Matthias ^a   Hu, Kai ^a   Hiller, Karl Heinz ^b   Galuppo, Paolo ^a   Fraccarollo, Daniela ^a   Schweizer, German ^a   Haase, Axel ^b   Ertl, Georg ^a   Bauer, Wolfgang R ^a   Bauersachs, Johann ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART EJECTION FRACTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART OUTPUT; HEART VENTRICLE REMODELING; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT;

ANIMALS; DISEASE MODELS, ANIMAL; HYDRALAZINE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIAL INFARCTION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PYRIDINES; RATS; RATS, WISTAR; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 0037032276     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02375-6     Document Type: Article

References (34)

1. Scandinavian Simvastatin Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-9.
2. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001;108:1429-37.
3. Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of mRNA levels for interleukin-1-beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPAR-alpha) in primary endothelial cells. Life Sci 2000;67:863-76.
4. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998;97:1129-35.
5. Mital S, Zhang X, Zhao G, et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol 2000;279:H2649-54.
6. Alvarez de Sotomayor M, Perrez-Guerrero C, Herrera MD, Marhuenda E. Effects of chronic treatment with simvastatin on endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 1999;17:769-76.
7. Wilson SH, Simari RD, Best PJ, et al. Simvastatin preserves endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001;21:122-8.
8. Kureihi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-10.
9. Luo JD, Xie F, Zhang WW, Ma XD, Guan JX, Chen X. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br J Pharmacol 2001;132:159-64.
10. Oi S, Osaki J, Kashiwagi Y, Nakamura Y, Kawabe J, Kikuchi K. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 1999;376:139-48.
11. Luo JD, Zhang WW, Zhang GP, Guan JX, Chen X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 1999;26:903-8.
12. Laufs U, Endres M, Stagliano N, et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest 2000;106:15-24.
13. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95.
14. Wollert KC, Studer R, von Bülow B, Drexler H. Survival after myocardial infarction in the rat: Role of tissue angiotensin-converting enzyme inhibition. Circulation 1994;90:2457-67.
15. 1-receptor subtype blockade in rats with myocardial infarction: Role of bradykinin. Cardiovasc Res 1998;39:401-12.
16. Nahrendorf M, Wiesmann F, Hiller KH, et al. In vivo assessment of cardiac remodeling after myocardial infarction in rats by cine-magnetic resonance imaging. J Cardiovasc Magn Reson 2000;3:171-80.
17. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications. Circulation 1990;81:1161-72.
18. Pfeffer MA, Pfeffer JM, Fishbein MC, et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979;44:503-12.
19. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol 1991;260:H1406-14.
20. Raya TE, Gay RG, Aguirre M, Goldman S. Importance of venodilation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: A comparison of captopril and hydralazine. Circ Res 1989;64:330-7.
21. G-nitro-L-arginine methyl ester-induced hypertension: Novel molecular adaption to systolic load in absence of hypertrophy. Circulation 2000;101:423-9.
22. Haase A, Frahm J, Matthaei M, Hänicke W, Merboldt KD. FLASH imaging: Rapid NMR imaging using low flip angle pulses. J Magn Reson 1986;67:258-66.
23. B receptor antagonist. Circulation 1996;93:2068-79.
24. Nahrendorf M, Wiesmann F, Hiller KH, et al. Serial assessment of cardiac remodeling after myocardial infarction in rats by cine-magnetic resonance imaging. J Magn Reson Imaging 2001;14:547-55.
25. Zierhut W, Rudin M, Robertson E, et al. Time course of spirapril-induced structural and functional changes after myocardial infarction in rats followed with magnetic resonance imaging. J Cardiovasc Pharmacol 1993;21:937-46.
26. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Circulation 1993;87:755-63.
27. Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000;35:985-91.
28. Anversa P, Beghi C, Kikkawa Y, Olivetti G. Myocardial infarction in rats: Infarct size, myocyte hypertrophy, capillary growth. Circ Res 1986;58:26-37.
29. Olivetti G, Capasso JM, Meggs LG, Sonnenblick EH, Anversa P. Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res 1991;68:859-69.
30. Waller C, Hiller KH, Kahler E, et al. Serial MR imaging of microvascular remodeling in the infarcted rat heart. Circulation 2001;103:1564-9.
31. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethyl-glutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001;104:982-5.
32. Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:317-24.
33. Hu K, Gaudron P, Weißmann J, von Schrader J, Fraccarollo D, Ertl G. Effects of acute or chronic nitric oxide synthesis inhibition on mortality, haemodynamics and remodelling in rats with myocardial infarction. Eur Heart J 1999;20 Suppl:171.
34. Pfeffer MA, Braunwald E, Moye LA, et al., the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.